Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs DENTSPLY SIRONA Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.11 (market cap $44.49B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 25.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| JEPQ | XRAY | |
|---|---|---|
Market Cap | $44.49B | $1.73B |
Volume | 5,681,789 | 6,198,582 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $14.68 |
52-Week Low | $53.77 | $8.52 |
Typical Hold Time | 66 Days | 72 Days |
Enterprise Value | — | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.09, down 0.29% on the day, with a bullish technical signal driven by moving averages. The ETF maintains strong income generation through its covered-call strategy, with recent monthly dividends ranging from $0.57 to $0.70. Technical analysis shows support at $60-61 and resistance at $61-62, while oscillators remain neutral with RSI at 47.13.
JEPQ offers high monthly income potential with an estimated 11% yield, though its covered-call strategy limits upside appreciation. The ETF provides exposure to Nasdaq technology stocks with downside protection during volatility. Key risks include market correlation, income variability, and competition from other income ETFs. Institutional interest remains strong, with Envestnet recently increasing its position.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
